Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.66 |
| ▸ | BTK | Q06187 | 8/20 | 0.66 |
| ▸ | ITK | Q08881 | 8/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | LYN | P07948 | 1/20 | 0.66 |
| ▸ | TEC | P42680 | 1/20 | 0.66 |
| ▸ | TXK | P42681 | 1/20 | 0.66 |
| ▸ | BMX | P51813 | 1/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.66 |
| ▸ | CD69 | Q07108 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544609 | 0.85 | EGFR (0.57) | EGFRBTKITKJAK2LYN | |
| SCHEMBL19544576 | 0.85 | EGFR (0.61) | EGFRBTKITKJAK2LYN | |
| SCHEMBL19544624 | 0.85 | EGFR (0.65) | EGFRBTKITKJAK2LYN | |
| SCHEMBL19544867 | 0.83 | SYK (0.48) | EGFRBTKITKJAK2LYN | |
| SCHEMBL19544866 | 0.81 | EGFR (0.44) | EGFRBTKITKJAK2LYN | |
| Spebrutinib SCHEMBL626216 | 0.80 | EGFR (1.00) | EGFRBTKITKJAK2LYN | |
| SCHEMBL29722399 | 0.80 | EGFR (1.00) | EGFRBTKITKJAK2LYN | |
| SCHEMBL12518308 | 0.80 | EGFR (1.00) | EGFRBTKITKJAK2LYN | |
| Spebrutinib SCHEMBL29359972 | 0.80 | EGFR (1.00) | EGFRBTKITKJAK2LYN | |
| SCHEMBL19624412 | 0.80 | EGFR (0.63) | EGFRBTKITKJAK2LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662174-B2 | BTK inhibitor | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662174-B2 | BTK inhibitor | BTK, SYK, LYN | EGFR 596/4885BTK 1/4885ITK 178/4885 |
| US-20170313683-A1 | BTK INHIBITOR | BTK, SYK, LYN | EGFR 596/4885BTK 1/4885ITK 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.